AACR Annual Meeting 2017

Continuing Medical Education (CME)

Accreditation Statement
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement
The AACR has designated this live activity for a maximum of 44.75 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey, below, by Wednesday, May 17, 2017. Certificates may be printed online after completing the Request for Credit Survey.

Statement of Educational Need, Target Audience, and Learning Objectives
With the accelerating pace of discoveries in the basic, translational and clinical sciences, due in large part to the advent of new technologies and also our increased understanding of the interplay between the immune system and cancer, cancer researchers are making rapid progress that is having significant patient benefit. By bridging the gap between what physicians understand about cancer biology and the clinical applications, this meeting aids basic researchers, physicians, and clinician-scientists in obtaining, synthesizing, and integrating the most cutting-edge research. This exposure is essential for the implementation of best practices, such as the most current molecular-based tests to aid in the diagnosis, treatment, and prevention of cancer. Further, facilitating the interface between physicians and scientists will increase knowledge of the epidemiological implications of cancer incidence and the contributions of laboratory research to drug development as well as patient care; transform the design and conduct of clinical research protocols; and create a forum for the rapid translation of laboratory research findings from “bench-to-bedside” for the benefit of improving patient outcomes.
Despite the tremendous progress in the field, cancer continues to be an enormous public health challenge worldwide, accounting for one in every seven deaths that occur around the world. In the United States (U.S.) alone, it is predicted that 595,650 people will die from some form of cancer in 2016, making it the second most common cause of death after heart disease.  One of the challenges we face is that cancer is comprised of more than 200 different diseases.  For many of the most commonly diagnosed cancers in the U.S.—including colorectal, lung, and prostate cancer—incidence has been declining for more than a decade.  However, incidence of other forms of cancer—including melanoma and kidney, liver, pancreatic and childhood cancer—have been on the rise. Overall five-year relative survival rates for U.S. patients vary widely depending on the form of cancer and the stage at which it is diagnosed. Incidence and survival rates are also impacted by the cancer health disparities that exist in certain segments of the U.S. population.
This conference will bring together investigators from the basic, translational, and clinical disciplines and provide them with a venue to discuss their recent advances, test new hypotheses, and establish new collaborations.  In order to have widespread implementation of the most current, approved molecular-based tests to aid in the diagnosis, treatment and prevention of cancer, it is critical to bridge the gap between what physicians understand about cancer biology and its application to clinical oncology.  As the incidence of cancer continues to increase, the fields of cancer prevention and early interception offer unprecedented opportunities to decrease the worldwide burden of cancer.

After participating in this CME activity, physicians should be able to:

1.  Recognize the technological advances and tools being used to accelerate progress in cancer research and improve early detection and early intervention, with the ultimate goal of extending patients' lives and improving their quality of life.

2.  Articulate how advances in precision cancer medicine are leading to improved patient outcomes. 

3.  Incorporate the latest research findings regarding therapies and treatment options, including immunotherapy, in a variety of cancer types in order to improve patient outcomes.

4.  Formulate new strategies that will further scientific and clinical research efforts towards the prevention and early detection of cancer.

5.  Identify factors which impact the diagnosis, treatment, and prevention of various forms of cancers in patients from different populations. 

6.  Develop collaborations amongst physicians, researchers, and clinician-scientists to advance the cause of treating and preventing cancer.

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR will provide information that Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. As part of AACR's policy on full disclosure of relevant financial relationships, the disclosure information is available in the Annual Meeting app, online planner, or conference website and is available for download.

Acknowledgement of Financial or Other Support
This activity is supported by grants and will be disclosed at the activity.

Questions about CME?
Please contact the Office of CME at 215-440-9300 or